Changes in TGF-beta mRNA in Breast Cancer Patients on Tamoxifen
Author Information
Author(s): JR Benson, AA Colletta
Primary Institution: Department of Surgery, Chelsea and Westminster Hospital
Hypothesis
How do transforming growth factor beta isoforms change in breast cancer patients undergoing tamoxifen therapy?
Conclusion
The study suggests that variations in TGF-beta expression may not be a reliable indicator of therapeutic response due to methodological issues.
Supporting Evidence
- Previous studies have shown mixed results regarding TGF-beta expression in breast cancer.
- Some studies indicate that TGF-beta may be regulated differently in early versus advanced stages of cancer.
- Immunohistochemical studies could provide more insight into TGF-beta protein levels.
Takeaway
This study looks at how a specific protein changes in breast cancer patients taking a medication called tamoxifen, but the results are complicated and hard to interpret.
Potential Biases
Potential bias due to the methodology allowing for significant intratumoral assay variation.
Limitations
The study's conclusions may be limited due to the age of participants and the size of their tumors.
Participant Demographics
Patients over 70 years of age with estrogen receptor positive tumors at least 3 cm in diameter.
Statistical Information
Statistical Significance
p<0.05
Want to read the original?
Access the complete publication on the publisher's website